Try our mobile app
PORTFOLIOS
Global Commodities
Trending Ideas
US Leaders
Eastern Europe
SCREENER
TOOLS
Inflation Prediction
US Insider trades
Calculator
Alpha Beta screener
OTHER
Dividend prediction
Gap closing statistics
Eastern European Strategy Signals
Resource Prices
Macro
ABOUT
SUBSCRIBE
DEPRECATED
Earnings calendar
IPO Calendar
Alpha Beta of our strategies
Rising Stars
JSE Exchange
Report Prediction Strategy
Report Prediction Strategy Backtest
Follow The Insiders
Follow The Insiders Backtest
Short Strategy
Short Strategy Backtest
Brave Ideas
Ray Dalio trades
Global Commodities Signals
Trending Ideas Signals
Rising Stars Signals
Toggle navigation
Page
Name
E-mail
Message
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Published: 2020-12-10 12:12:00 ET
<<< go to TGTX company page
Both
studies
met their primary endpoint of
significantly reducing
annualized relapse rate (
ARR
)
(p